我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
91
9 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
7
7.7%
已完成
64
70.3%
尚未招募
2
2.2%
招募中
9
9.9%
终止
撤回
暂无批准数据
- Melbourne-based PolyActiva raised $40 million in Series C funding, including $27 million from Australia's National Reconstruction Fund, to advance its biodegradable glaucoma treatment implant. - The company's innovative two-millimeter polymer implant delivers medication directly into the eye over six months, potentially eliminating daily eye drops for glaucoma patients. - With Phase 2B clinical trials underway, PolyActiva aims to commercialize the technology by 2029 while maintaining its Australian headquarters and expanding local manufacturing capabilities. - The funding addresses a critical need for the 80 million people globally affected by glaucoma, a number expected to reach 111 million by 2040.
